KESTRA MEDICAL TECHNOLOGIES, LTD.(KMTS)Stock Analysis

KMTS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KMTS at 30.8/100 on a 32-signal composite quality model, placing it at rank #2,347 of 2,879 stocks — the bottom half of the AI-ranked universe. KMTS scores in the top quartile across institutional flow (94.9), revenue growth (92.5). Areas of concern include balance sheet strength (5.7) and free cash flow (6.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), KESTRA MEDICAL TECHNOLOGIES, LTD. reports quarterly revenue of $28.6M, net income of $-38.8M, free cash flow of $-28.4M. Top institutional holders of KMTS by reported 13-F value include BAIN CAPITAL INVESTORS, FMR, Andera Partners, based on the most recent SEC filings. KMTS trades on the Nasdaq exchange and files with the SEC under CIK 1877184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KMTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KESTRA MEDICAL TECHNOLOGIES, LTD. directly from SEC EDGAR.